Skin microenvironment targeted delivery for promoting immune and other responses
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsLouis D. Falo, Jr., Adriana Teresita Larregina De Morelli
Life of this patent
Estimating the term…
Abstract
Methods are provided for promoting, reducing, or desensitizing various immune responses by delivery of sub-immunogenic doses of an allergen, alone or with other agents, or by delivery of antigens and adjuvants to a cutaneous microenvironment of a subject. Microneedle arrays can be used in connection with this delivery.
Claims14
A method for reducing or desensitizing an immune response of a subject in need thereof, the method comprising:
- selecting one or more doses of an antigen or allergen for delivery to a cutaneous microenvironment of the subject,
- selecting one or more immune suppressants and/or tolerizing agents to the cutaneous microenvironment, the one or more immune suppressants and/or tolerizing agents comprises at least one selected from the group of NK1R antagonists,
- incorporating the one or more doses of the antigen or allergen and the one or more immune suppressants and/or tolerizing agents into a dissolvable microneedle array,
- applying the microneedle array to the cutaneous microenvironment of the subject thereby administering the one or more doses of the antigen or allergen to the cutaneous microenvironment, and administering the one or more immune suppressants and/or tolerizing agents to the cutaneous microenvironment,
- reducing or desensitizing the immune response of the subject by the administration of the one or more doses.
A method for reducing or desensitizing an immune response of a subject in need thereof, the method comprising:
- administering one or more doses of an antigen or allergen to a cutaneous microenvironment of the subject,
- reducing or desensitizing the immune response of the subject by the administration of the one or more doses,
- and
- wherein the antigen or allergen is DNBS and the one or more doses of DNBS is 100 ng or less.
Dependencies are inferred from the claim text.